Musk Confidant Afshar Leaves Tesla in Latest High-Level Exit
US Renters Face Storm of Rising Costs
US State Budget Wounds Intensify From Trump, DOGE Policy Shifts
Mapping the Architectural History of New York's Chinatown
Squeezed by Crowds, the Roads of Central Park Are Being Reimagined
Commuters Are Caught in Johannesburg's Taxi Feuds as Transit Lags
News of the exit has circulated internally among some employees in recent days, said the people, who asked not to be identified discussing internal information. Afshar's name no longer appeared to show up in an internal directory, two of the people said. The reason for the change and his future plans weren't immediately clear.
Some of the directors who reported to Afshar now report to Tom Zhu, Tesla's senior vice president of automotive, according to some of the people. The Chinese-born executive oversees Tesla's factory in Shanghai and is one of the company's three named executive officers.
Afshar, Musk, Zhu and Tesla didn't immediately respond to requests for comment.
Afshar, who has worked in the office of the CEO, was promoted last year to oversee sales and manufacturing operations in North America and Europe. Those markets have become particular pain points for the automaker recently, with sales plunging due to rising competition and a consumer backlash to Musk's role in US President Donald Trump's administration.
This marks the latest departure of a prominent Tesla leader in recent weeks. Milan Kovac, the head of engineering for the company's Optimus humanoid robot program, stepped down citing a desire to spend more time with his family.
Jenna Ferrua, who is listed on LinkedIn as a human resources director for North America, has also left Tesla and no longer appears to be in the company directory, according to people familiar.
The personnel changes punctuate a tumultuous year for Tesla, whose shares have tumbled about 19% while demand has waned for its EV models and Musk has spent time in Washington. The chief executive officer is trying to reorient the company around artificial intelligence, robots and driverless cars, recently rolling out a small number of Tesla's long-promised robotaxis in Austin.
Tesla is expected to report global delivery results for the second quarter next week.
Its shares briefly turned negative after Bloomberg reported Afshar's departure, and were little changed as of 1:57 p.m. in New York.
Tesla Tenure
Afshar joined Tesla in 2017, according to his LinkedIn profile, as the carmaker was beginning to ramp up production of the Model 3 sedan.
'I was with Elon nearly every single day during Model 3 hell,' he said in a 2024 post on X, the social media platform that Musk owns. 'This included Thanksgiving, Christmas, New Year's Eve, his birthday and nearly missing his brother's wedding.'
Afshar was posting regularly on social media in recent days, including several messages this week praising the robotaxi launch.
The executive oversaw the construction of Tesla's plant in Austin. A member of the office of the CEO since 2017, his most recent job title was listed on his LinkedIn page as a cowboy hat emoji.
He came under internal scrutiny in 2022 for his role in purchasing hard-to-get construction materials, including a special kind of glass, Bloomberg reported.
It's not unusual for executives to shuffle from one part of Musk's empire to another, and Afshar worked at SpaceX for a time.
Tesla has just three named executive officers: Musk, Chief Financial Officer Vaibhav Taneja and Zhu.
--With assistance from Kara Carlson and Craig Trudell.
(Updates shares, adds directors reporting to Zhu from the third paragraph. )
How to Steal a House
Inside Gap's Last-Ditch, Tariff-Addled Turnaround Push
Apple Test-Drives Big-Screen Movie Strategy With F1
America's Top Consumer-Sentiment Economist Is Worried
Luxury Counterfeiters Keep Outsmarting the Makers of $10,000 Handbags
©2025 Bloomberg L.P.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Editorial: More unlawful tariffs: Trump has no authority to institute damaging trade barriers
On Friday, Donald Trump followed up a concerning jobs report with massive new global tariffs, driving markets down and once more raising prices on consumers for no reason after weeks of supposed trade negotiations. Like with his first round of import duties, announced in the Rose Garden on his ludicrous April 2 'Liberation Day,' these tariffs are not only chaotic and destructive, but they're illegal. The president is leaning on a 1977 law meant to be invoked for targeted financial actions in certain emergency circumstances to reshape trade globally. Just the day before these newest tariffs were implemented, the administration's lawyers had been grilled by the 11 judges of the U.S. Court of Appeals for the Federal Circuit in Washington, who pointed out among other things that the law doesn't even mention tariffs at all. If the plaintiffs, made up of states and businesses, need anywhere to look for inspiration and evidence for their legal arguments, they don't have to look much further than Trump's own ramblings and social media feed, where he constantly tells the whole world that he is engaging in the tariff actions for all manner of reasons completely unrelated to any economic objectives. So far, he's threatened tariffs over Brazil's domestic prosecution of its former president Jair Bolsonaro and over Canada's intent to recognize a Palestinian state, among other things. This is a real disparate set of rationales, but what they have in common is that they are ideological battles probably drawn from something Trump saw on TV and have nothing to do with correcting a supposed trade imbalance with those countries, already an incredibly flimsy argument to begin with. Don't just take our word for it; the Manhattan-based U.S. Court of International Trade — you know, the judicial entity set up specifically and explicitly to have expertise on these matters — already struck down most of Trump's tariff regime on the grounds that it was unlawful. That ruling has been stayed for now, but the evidence just keeps piling on that Trump is significantly exceeding his authority. Unfortunately, even if this insanity were to be fully struck down tomorrow, we've had months of chaos that has indelibly damaged trade relationships as well as general diplomatic relations. The world is not going to wait for the U.S. to hash out its chaos, and other countries are already moving to reorient parts of their manufacturing and trade schemes to circumvent an unreliable United States. Of course, this seems like one more issue headed at some point to the U.S. Supreme Court, perhaps the shadow docket where the court these days like to conduct its unsigned pro-Trump business. It's long since become clear that the high court is more interested in ideological outcomes than the uniform application of the law, but even then, siding with Trump here would be farcical. This is the exact same court that just last year ruled that Joe Biden attempting to clear some student debt by invoking emergency powers in the context of the COVID pandemic — a real global catastrophe that killed countless people and crashed the economy while putting millions out of work — was an unlawful exercise of authority. If that's the case, but Trump is in his rights to wildly alter tariff policies at a whim in service to random political grievances around the world, then the law truly means nothing anymore. Let's stop this madness while we still can, before economic forces take it out of our hands. ___
Yahoo
24 minutes ago
- Yahoo
Market Accelerates with Key Players Like Merck and Moderna, Backed by Pharma-Biotech Collaborations and Academic Partnerships
The global cancer vaccine market is experiencing robust growth driven by rising cancer cases, advancements in immunotherapy, and novel vaccine development technologies. Both preventive (e.g., HPV, HBV) and therapeutic vaccines are gaining traction, supported by increased R&D investments, especially in mRNA platforms and neoantigen vaccines. Innovations like AI and genome sequencing are enhancing personalized therapies, while FDA approvals boost confidence in clinical efficacy. With strong healthcare infrastructure in North America and Europe, and rising demand in Asia-Pacific, the market is poised for continued expansion, despite challenges like high R&D costs and complex regulations. Leading companies include Merck, Dynavax, and Moderna, with future growth focusing on personalized medicine, next-gen platforms, and oncology research funding. Dublin, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The "Cancer Vaccine Market - A Global and Regional Analysis: Focus on Vaccine Type, Technology Type, and Region - Analysis and Forecast, 2025-2035" report has been added to global cancer vaccine market is witnessing significant growth due to rising cancer prevalence, increasing adoption of immunotherapies, and advancements in vaccine development technologies. Cancer vaccines, both preventive and therapeutic, aim to stimulate the immune system to prevent or combat cancer. While preventive vaccines such as HPV and HBV vaccines have achieved broad adoption, therapeutic cancer vaccines are gaining traction with the development of personalized and targeted in the cancer vaccine market is supported by the growing investments in R&D, particularly in mRNA vaccine platforms and neoantigen-based vaccines, are fuelling innovation across the cancer vaccine market. Companies are leveraging AI and genome sequencing to design individualized vaccines targeting tumor-specific mutations. The FDA approvals of vaccines such as Sipuleucel-T and BCG for prostate and bladder cancer, respectively, have further validated the clinical potential of cancer increasing incidence of cancer globally, alongside unmet medical needs in oncology, is driving demand for novel vaccine approaches that can provide long-term immune memory and minimal side effects. Immunotherapy's success in other areas has also increased confidence in vaccine-based cancer treatments, spurring regulatory support and clinical trials across solid and hematologic market growth is underpinned by strong healthcare infrastructure in North America and Europe, rising awareness, and supportive reimbursement policies. The Asia-Pacific region is emerging as a high-growth area due to expanding healthcare access, government initiatives, and local manufacturing capabilities. The cancer vaccine market will continue to evolve with a strong focus on therapeutic innovations, including neoantigen-targeted and mRNA-based approaches. Advancements in precision oncology and global commitment to reducing cancer burden will shape the trajectory of the cancer vaccine market as a cornerstone of future cancer positive growth prospects, the cancer vaccine market faces challenges such as high R&D costs, complex regulatory pathways, and limited efficacy of some therapeutic vaccines. Additionally, patient-specific manufacturing and storage logistics for personalized vaccines pose scalability competitive landscape includes major players such as Merck, Dynavax Technologies and Dendreon, as well as innovative biotech firms like Moderna, BioNTech, Transgene, Imugene, and OSE Immunotherapeutics. Collaborations between pharma and biotech companies, academic institutions, and research consortia are accelerating pipeline ahead, the cancer vaccine market is projected to grow steadily, driven by the expansion of personalized medicine, next-generation vaccine platforms, and increased funding for oncology research. Integration of digital health for patient tracking and AI-assisted trial designs is expected to optimize treatment outcomes and regulatory timelines. Key Topics Covered: 1. Global Cancer Vaccine Market: Industry Analysis1.1 Market Overview and Ecosystem1.2 Epidemiological Analysis1.3 Key Market Trends1.3.1 Impact Analysis1.4 Patent Analysis1.4.1 Patent Filing Trend (by Country)1.4.2 Patent Filing Trend (by Year)1.5 Regulatory Landscape1.6 Ongoing Clinical Trials1.7 Market Dynamics1.7.1 Overview1.7.2 Market Drivers1.7.3 Market Restraints1.7.4 Market Opportunities2. Global Cancer Vaccine Market, by Vaccine Type, $Million, 2023-20352.1 Preventive Vaccines2.1.1 Gardasil2.1.2 HEPLISAV-B2.2 Therapeutic Vaccines2.2.1 Bacillus Calmette-Guerin (BCG)2.2.2 Sipuleucel-T (Provenge)3. Global Cancer Vaccine Market, by Technology Type, $Million, 2023-20353.1 Recombinant3.2 Cell-based3.3 Others4. Global Cancer Vaccine Market, by Region, $Million, 2023-20354.1 North America4.1.1 Market Dynamics4.1.2 Market Sizing and Forecast4.1.3 North America Cancer Vaccine Market, by Country4.1.3.1 U.S.4.2 Europe4.2.1 Market Dynamics4.2.2 Market Sizing and Forecast4.2.3 Europe Cancer Vaccine Market, by Country4.2.3.1 U.K.4.2.3.2 France4.2.3.3 Germany4.2.3.4 Italy4.2.3.5 Spain4.3 Asia-Pacific4.3.1 Market Dynamics4.3.2 Market Sizing and Forecast4.3.3 Asia-Pacific Cancer Vaccine Market, by Country4.3.3.1 Japan5. Global Cancer Vaccine Market, Competitive Landscape and Company Profiles5.1 Competitive Landscape5.1.1 Mergers and Acquisitions5.1.2 Partnership, Alliances and Business Expansion5.1.3 New Offerings5.1.4 Regulatory Activities5.1.5 Funding Activities5.2 Company Profiles5.2.1 Overview5.2.2 Top Products / Product Portfolio5.2.3 Top Competitors5.2.4 Target Customers/End-Users5.2.5 Key Personnel5.2.6 Analyst View Merck & Co., Inc., Dynavax Technologies Corporation Dendreon Pharmaceuticals LLC Moderna, Inc BioNTech SE Transgene S.A. Imugene Limited Ose-Immuno Barinthus Biotherapeutics For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Orphan Drug Incentives, Innovative Cysteamine Delivery, Gene Therapy Potential, and Early Diagnosis Fueling Advancements
The cystinosis market is poised for growth amid increasing newborn screening, innovative cysteamine formulations, and potential gene therapy breakthroughs. As a rare metabolic disorder, cystinosis is marked by cystine accumulation, primarily affecting kidneys and eyes. While cysteamine remains a cornerstone treatment, its long-term use presents challenges. Advances in gene therapy trials, renal transplantation, and metabolic screening are enhancing patient management. North America leads the market, followed by Europe, with Asia-Pacific showing rising potential. Key players like Recordati Rare Diseases and Amgen drive the competitive landscape, offering new opportunities in this focused healthcare segment. Dublin, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The "Cystinosis Market - A Global and Regional Analysis: Focus on Type, Drug Class, and Region - Analysis and Forecast, 2025-2035" report has been added to development of delayed release cysteamine formulations, ongoing gene therapy trials, and improvements in renal transplantation techniques are reshaping disease management. Technological advancements in metabolic screening and growing collaboration among stakeholders are enabling more effective and accessible treatment advancements, challenges persist such as treatment adherence, side effects of long-term cysteamine use, and limited availability of specialized care in low-income regions. Nonetheless, the growing focus on rare disease awareness, expansion of clinical trials, and regulatory support for orphan drugs are expected to sustain market America is expected to dominate the cystinosis market owing to advanced healthcare systems, robust rare disease registries, and presence of key market players. Europe follows closely, driven by strong orphan drug policies and centralized healthcare systems. Asia-Pacific shows emerging growth potential due to increasing rare disease awareness and investment in genetic diagnostics. Key Market Players and Competition Synopsis The companies profiled in this report have been selected based on their market presence, product portfolio, and competitive positioning in the global cystinosis market. How can this report add value to an organization?Product/Innovation: This report provides comprehensive insights into the current trends in cystinosis, helping companies identify opportunities for drug and technology development. Organizations can leverage these insights to design therapies, medications, and platforms tailored to the needs of patients suffering from cystinosis, improving outcomes and enhancing market A detailed competitive landscape analysis helps organizations benchmark their market standing against key players. By understanding the strengths and weaknesses of competitors, companies can position themselves more effectively in the global cystinosis Drivers and Limitations Demand Drivers for the Global Cystinosis Market: Increasing newborn screening and early diagnosis rates Continued innovation in cysteamine formulations and delivery systems Emergence of gene therapy as a potentially curative treatment Regulatory incentives and support for orphan drugs Limitations for the Global Cystinosis Market: High cost and side effects of lifelong pharmacological treatment Limited access to expert care and specialized facilities in developing regions Treatment adherence challenges among pediatric patients Leading players in the global cystinosis market include: Recordati Rare Diseases Amgen Inc Viatris Inc Leadiant Biosciences, Inc Novartis AG Nacuity Pharmaceuticals, Inc CHIESI Farmaceutici S.p.A. Papillon Therapeutics Inc Key Topics Covered: 1. Global Cystinosis Market: Industry Analysis1.1 Market Overview and Ecosystem1.2 Epidemiological Analysis1.3 Key Market Trends1.3.1 Impact Analysis1.4 Patent Analysis1.4.1 Patent Filing Trend (by Country)1.4.2 Patent Filing Trend (by Year)1.5 Regulatory Landscape1.6 Ongoing Clinical Trials1.7 Market Dynamics1.7.1 Overview1.7.2 Market Drivers1.7.3 Market Restraints1.7.4 Market Opportunities2. Global Cystinosis Market, by Type, $Million, 2023-20352.1 Nephropathic Cystinosis2.2 Intermediate Cystinosis2.3 Non-Nephropathic Cystinosis3. Global Cystinosis Market, by Drug Class, $Million, 2023-20353.1 Cysteamine Bitartrate (Immediate-Release)3.2 Cysteamine Bitartrate (Delayed-Release)3.3 Others4. Global Cystinosis Market, by Region, $Million, 2023-20354.1 North America4.1.1 Market Dynamics4.1.2 Market Sizing and Forecast4.1.3 North America Cystinosis Market, by Country4.1.3.1 U.S.4.2 Europe4.2.1 Market Dynamics4.2.2 Market Sizing and Forecast4.2.3 Europe Cystinosis Market, by Country4.2.3.1 U.K.4.2.3.2 France4.2.3.3 Germany4.2.3.4 Italy4.2.3.5 Spain4.3 Asia-Pacific4.3.1 Market Dynamics4.3.2 Market Sizing and Forecast4.3.3 Asia-Pacific Cystinosis Market, by Country4.3.3.1 Japan5. Global Cystinosis Market, Competitive Landscape and Company Profiles5.1 Competitive Landscape5.1.1 Mergers and Acquisitions5.1.2 Partnership, Alliances and Business Expansion5.1.3 New Offerings5.1.4 Regulatory Activities5.1.5 Funding Activities5.2 Company Profiles5.2.1 Overview5.2.2 Top Products / Product Portfolio5.2.3 Top Competitors5.2.4 Target Customers/End-Users5.2.5 Key Personnel5.2.6 Analyst View For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
